On December 2, 2020 AAM filed a brief in the Supreme Court in U.S. v. Arthrex, the latest constitutional challenge to IPR – urging the Court to uphold the system. Among other things, the brief explains how IPR is a necessary tool to combat pharmaceutical patent abuse.
Generic and biosimilar medicines make it easier and more affordable for patients to live healthier lives.
Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.
For the latest updates, follow us on social media.
